Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SAN JOSE, Calif.--(BUSINESS WIRE)--DFINE, Inc., the developer of minimally invasive radiofrequency (RF) targeted therapies for the treatment of vertebral pathologies, announced results presented this week at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The presentation entitled “Targeted Radiofrequency Ablation™ (t-RFA) of Metastatic Posterior Vertebral Body Lesions in Patients With Soft Tissue Sarcomas,” highlighted successful treatment outcomes in radioresistant tumors using the DFINE STAR™ Tumor Ablation System.
Help employers find you! Check out all the jobs and post your resume.
